At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
Low Dose of KBP-COVID-19 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85
In Brief
A Phase 2 clinical trial evaluating Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, and 1 other intervention for Covid19. Completed, enrolled 102 participants across 8 sites in 2 countries.
Detailed Summary
This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 plus CPG adjuvant vaccine in healthy adult subjects in 2 age groups, Part A (18-49 years) and Part B (50-85 years).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartDec 2020
Primary CompletionMay 2022
Study CompletionOct 2022
TodayJul 2026
First PostedJul 16, 2020
Enrollment StartDec 30, 2020
Primary CompletionMay 31, 2022
Study CompletionOct 14, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.0 years ago
Interventions
Low Dose of KBP-COVID-19biological
Low Dose of KBP-COVID-19 and adjuvant
High Dose of KBP-COVID-19biological
High Dose of KBP-COVID-19 and adjuvant
Placebobiological
Buffered saline solution